Everyone's sick this winter. What's up with flu, norovirus, RSV and COVID?
Everyone's sick this winter. What's up with flu, norovirus, RSV and COVID?
Show Caption
Hide Caption
Flu cases on the rise nationwide
Of the 50 states, 40 are reporting high or very high levels of flu activity. Nearly released data shows the current U.S. flu season is shattering records.
Fox - Milwaukee
If it seems like you and everyone around you is getting sick this winter, you're not wrong.
Experts say this is the worst flu season in the U.S. in more than a decade and cases are still trending up. Flu infections have reached the highest level since the winter of 2010 and 2011 when the swine flu swept across the nation, data from the Centers for Disease Control and Prevention shows.
The surge in flu cases also comes amid concerns about high infection rates for other viruses including RSV, COVID-19 and the gastrointestinal bug norovirus. Still, health officials say flu cases are among their top concerns right now.
For the first time since the COVID-19 pandemic began five years ago, flu-related deaths topped COVID-19-related ones this winter.
Those numbers reflect just how intense this year's influenza season has been, said Jen Brull, president of the American Academy of Family Physicians.
'It's not that COVID-19 is getting better, it's that influenza is getting worse,' Brull said. "It sounds like, 'Oh, good, COVID deaths are going down,' but really it's just influenza illness and deaths are going up."
Flu season by the numbers
The CDC estimates that there have been at least 29 million flu infections so far this season, through Feb. 8, including 370,000 hospitalizations and 16,000 deaths.
While some years the flu disproportionately affects people of certain age groups, the agency described this year as a high severity season for people of all ages. For instance, the number of people who have so far visited the doctor for flu-like symptoms in February has spiked higher than during the same timeframe in 2020 at the beginning of the COVID-19 pandemic.
And last year, the CDC estimated that the flu caused a total of 470,000 hospitalizations and 28,000 deaths.
Brull, who also works as a family physician in Colorado, said flu cases typically swell in February just when it seems like the winter virus season is ending.
This year's surge in infections and hospitalizations appears larger than in the past, suggesting that this strain of influenza virus is 'more contagious' and 'more severe' than in past years, she said. If cases remain high throughout February, as they are expected to, Brull told USA TODAY flu deaths could triple from last year.
Why are flu cases surging?
The severity of this year's flu season is driven by a combination of factors, experts suggested.
Daniel Griffin, an infectious disease specialist at Columbia University, said the uptick could be a result of people socializing more this year than they did in the immediate years after the pandemic.
Vaccination rates might also be playing a role, Brull said.
Flu vaccination rates among the general population are at their lowest level in three years, according to CDC data. Among children, they're at a six-year low.
'Any family physician would tell you it is not too late to get your flu shot or your COVID booster this year,' Brull said. 'Flu and COVID exist all year round.'
A confluence of illnesses
This year's cold and flu season has also seen spikes in other illnesses, including COVID-19, RSV and the gastrointestinal-related norovirus.
There were more norovirus cases between November and January of this year than at any point going back to at least 2012, according to CDC data. Infections related to that virus appear to be on the decline for this season.
The number of people heading to the emergency room for RSV and COVID-19 infections also is decreasing across much of the country, though wastewater data collected by the CDC suggests that COVID-19 infections are still high.
Griffin said the flu is 'the most common' illness infectious disease consultants are being called for in hospitals right now.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Biden's COVID czar hammers RFK Jr. over vaccine panel overhaul
Former White House COVID-19 response coordinator Ashish Jha, who served under former President Biden, criticized the decision by Health and Human Services Secretary Robert F. Kennedy Jr. to fire all 17 experts on the U.S. Centers for Disease Control and Prevention's (CDC) vaccine panel. Kennedy announced the decision in an op-ed for The Wall Street Journal on Monday, saying, 'A clean sweep is needed to re-establish public confidence in vaccine science.' But in an interview with CNN's Wolf Blitzer, Jha pushed back against Kennedy's reasoning. 'Look, what he said in his op-ed was a series of nonsense about a group of individuals, experts …who shape what vaccines, if any, are going to be available to the American people,' Jha said in the interview. 'So obviously this is very concerning,' he continued. 'We'll have to see who he appoints next. But this is a step in the wrong direction.' Jha said he is concerned about what the move foretells about the secretary's agenda on vaccines. Jha pointed to what he characterized as a lackluster response from the secretary to 'the worst measles outbreak of the last 25 years.' He also expressed concern regarding Kennedy's raising questions about vaccines causing autism, which Jha dismissed and said was 'settled science.' 'Then you put this in the middle of all of that,' Jha said, referring to the vaccine panel sweep, 'and what you have is a pretty clear picture that what Secretary Kennedy is trying to do is make sure that vaccines are not readily available to Americans, not just for kids, for the elderly.' 'He could go pretty far with this move, and I really am worried about where we're headed,' Jha continued. He said he's particularly concerned about the effect Kennedy's move will have on kids and whether they will continue having access to certain vaccines in the future. 'Kids rely on vaccines. I'm worried about whether the next generation of kids are going to have access to polio vaccines and measles vaccines. That's where we're heading. That's what we have to push back against.' Kennedy said in his op-ed that he was removing every member of the panel to give the Trump administration an opportunity to appoint its own members. Kennedy has long accused members of the Advisory Committee on Immunization Practices of having conflicts of interest, sparking concern among vaccine advocates that he would seek to install members who are far more skeptical of approving new vaccines. But Jha pushed back against criticism that the panel was all Biden-appointed experts, saying, 'When the Biden administration came in, almost all of the appointees had come from the first Trump administration.' 'That was fine because they were good people,' he said. 'They were experts. Right now, it's the same thing. The people he is firing are experts — like a nurse in Illinois who spent her entire career getting kids vaccinated, cancer doctors from Memorial Sloan Kettering — like these are really good people.' 'And generally, CDC has not worried about when were they appointed. The question is, are they good and are they conflict free.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
7 hours ago
- Yahoo
UAMS chancellor stepping down after 7 years, returning to faculty
UAMS Chancellor Cam Patterson announces a new $31.7 million grant from the National Institutes of Health on July 10, 2024. (Mary Hennigan/Arkansas Advocate) The leader of Arkansas' largest healthcare system will step down after seven years for personal and medical reasons, the University of Arkansas for Medical Sciences announced Tuesday in a news release. Dr. Cam Patterson became the university's chancellor in June 2018. By giving up his position as chancellor and as UAMS Health CEO, he will return to being a faculty member in the university's cardiology department. Patterson 'is facing medical and personal issues that require more attention than he can give them while serving in the chancellor's position,' according to UAMS' news release. 'The work our team has done at UAMS over the last seven-plus years has been the high point of my career,' Patterson said in the release. 'We have a lot to be proud of and I've been the luckiest guy to be a part of it. I am excited about the opportunity to return to the faculty and engage more deeply in the academic and clinical missions at our institution.' UAMS System President Jay Silveria praised Patterson's leadership tenure in the release. 'Leading UAMS is a demanding task, and I appreciate Dr. Patterson's need to do what he feels is best for himself and his family and for the long-term success of the university,' Silveria said. 'His contributions to UAMS came through unusually restrictive times, and he should be celebrated for his efforts to push the institution forward while navigating a challenging environment.' Patterson 'oversaw both challenges and improvement in the university's economic outlook, despite the myriad issues presented by the COVID-19 pandemic and other unforeseen variables,' the release states. One such challenge was a conflict between state and federal mandates regarding COVID-19 vaccinations. The federal Centers for Medicare and Medicaid Services issued a mandate in November 2021 for health workers to be fully vaccinated or receive exemptions, with noncompliant facilities at risk of losing federal funding. The rule directly conflicted with a 2021 Arkansas law that said COVID-19 vaccination 'shall not be a condition of education, employment, entry, or services from the state or a state agency or entity' unless lawmakers approved an exception. Patterson sought an exemption and defended this decision before a legislative committee. Silveria will name an interim UAMS chancellor 'in the coming weeks' and start a national search for Patterson's permanent successor, the news release states. SUPPORT: YOU MAKE OUR WORK POSSIBLE
Miami Herald
7 hours ago
- Miami Herald
Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue
Even the Hamburglar didn't see this one coming. Excessive weight has been a persistent problem in America, where at least one in five adults in each U.S. state is living with obesity, according to the Centers for Disease Control and Prevention. Don't miss the move: Subscribe to TheStreet's free daily newsletter As obesity rates have risen, so have scientists' efforts to address this serious health issue, which can cause asthma, heart disease, stroke, type 2 diabetes and even some cancers. Early attempts to treat obesity came to the market as early as the 1930s. Amphetamines were the prevalent treatment in the 1940s and 1950s and demand continued into the 1990s. Glucagon-like peptide-1 agonists, which mimic the action of the naturally occurring hormone GLP-1, have been available for about two decades. GLP-1 medications, including Ozempic, Wegovy, Zepbound and Mounjaro, have been used for years to treat Type 2 diabetes, and studies have found that they are also effective at encouraging weight loss. Wegovy and Ozempic are manufactured by Novo Nordisk (NVO) , while Eli Lilly (LLY) makes Zepbound and Mounjaro. Image source:One investment firm says increased use of these medications could have serious implications for two of the biggest names in the fast-food industry: McDonald's (MCD) and Domino's Pizza (DPZ) . The market for anti-obesity drugs, particularly those using injectable versions of GLP 1-based drugs, is still new and continuously evolving, Goldman Sachs said in a May 22 report. More Restaurants Beloved Mexican restaurant closing iconic location after 63 yearsMajor restaurant chain quietly closes several locationsIconic restaurant closing its doors after 32 years The investment firm lowered its projections for such medication and now forecasts the global market to reach $95 billion by 2030. That's down from the previous estimate of $130 billion to reflect trends influencing how the drugs are priced, how long patients stay on them, and how patient populations are segmented. Goldman lowered its U.S. market projections to a peak of $70 billion, but the firm sees room for greater penetration in markets outside the U.S. Goldman forecasts a market peak of $50 billion outside the US, compared with $35 billion previously. A survey of more than 50 doctors in the US found that lower doses of anti-obesity medications are working well for a majority of patients and insurance coverage is the most important factor in the decision-making process, Goldman Sachs wrote. "But to be clear, even with this moderated forecast, we see a significant growth opportunity for both existing players as well as new entrants into this market," said Asad Haider, head of the health-care business unit within Goldman Sachs Research. Demand for GPL-1 drugs could dramatically hinder the food and restaurant industries, according to a study from Cornell's SC Johnson College of Business and the data firm Numerator. The report, entitled "The No Hunger Games," found that households with at least one user of GLP-1 drugs reduced its grocery spending by about 6% within six months of starting the drugs. The spending cut was as much as 9% for higher-income households. "We also find an 8.6% decline in spending at fast-food chains, coffee shops and limited-service restaurants," the study said. "Our findings highlight the potential for GLP-1 medications to significantly change food demand, a trend with increasingly important implications for the food industry as GLP-1 adoption continues to grow." The study warned that common side effects of GLP-1 medications, such as nausea, vomiting and gastrointestinal discomfort, have reportedly led to reduced adherence or discontinued use for some patients. Related: McDonald's analyst grills new stock price target on McCrispy reaction "Moreover, their long-term efficacy and safety remain areas of ongoing investigation," the report said. Redburn Atlantic analyst Chris Luyckx focused on the growing adoption of GLP-1 in recent research reports. Luyckx double-downgraded McDonald's to sell from buy with a price target of $260, down from $319. The analyst expects the GLP-1 weight-loss drugs to suppress consumer appetites and says they present an underappreciated longer-term threat for McDonald's. A 1% drag on sales today "could easily build to 10% or more over time," particularly for restaurant brands skewed toward lower-income consumers, the analyst tells investors in a research note. McDonald's stock was down about 1.3% at last check and is up 18.5% from a year ago. Redburn Atlantic also initiated coverage of Domino's Pizza with a sell rating and $340 price target. Domino's, the world's largest pizza chain, faces the heaviest pressure from adoption of GLP-1 weight loss drugs, with high exposure to dinner occasions and lower-income consumers, the firm said. Redburn Atlantic said the company's organic traffic remains weak, with carry-out far outpacing delivery. Challenged system-sales growth and elevated consensus expectations present downside risk for Domino's, the firm said. McDonald's closed regular trading on June 10 down 1.4% at $300.43. Domino's shares were off 2.7% at $455.49. Related: Fund-management veteran skips emotion in investment strategy The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
